Duration of Postvaccination Neutralizing Antibodies to SARS-CoV-2 and Medication Effects: Results from the Safety and Immunogenicity of COVID-19 Vaccination in Systemic Immune-Mediated Inflammatory Diseases Cohort Study

被引:0
|
作者
Habib, Rami [1 ]
Dayam, Roya M. [2 ]
Hitchon, Carol [3 ]
Chandran, Vinod [4 ,5 ]
Fortin, Paul R. [6 ]
Boire, Gilles [7 ]
Bowdish, Dawn M. E. [8 ]
Gingras, Anne-Claude [2 ]
Flamand, Louis [6 ,9 ]
Larche, Maggie J. [8 ]
Colmegna, Ines [1 ]
Lukusa, Luck [1 ]
Lee, Jennifer L. F. [1 ]
Pereira, Daniel [10 ]
Bernstein, Charles N. [3 ]
Lalonde, Nadine [11 ]
Turnbull, Elizabeth [1 ]
Bernatsky, Sasha [1 ]
机构
[1] McGill Univ, Montreal, PQ, Canada
[2] Mt Sinai Hosp, Sinai Hlth, Toronto, ON, Canada
[3] Univ Manitoba, Winnipeg, MB, Canada
[4] Univ Hlth Network, Schroeder Arthrit Inst, Krembil Res Inst, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Univ Laval, Ctr Hosp Univ CHU Quebec, Res Ctr, Quebec City, PQ, Canada
[7] Univ Sherbrooke, Sherbrooke, PQ, Canada
[8] McMaster Univ, Hamilton, ON, Canada
[9] Univ Laval, Quebec City, PQ, Canada
[10] Univ Hlth Network, Schroeder Arthrit Inst, Krembil Res Inst, Toronto, ON, Canada
[11] Canadian Arthrit Patient Alliance, Toronto, ON, Canada
关键词
D O I
10.1002/acr2.11697
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveIn the face of the ongoing circulation of SARS-CoV-2, the durability of neutralization post-COVID-19 vaccination in immune-mediated inflammatory disease (IMID) is a key issue, as are the effects of medications.MethodsAdults (n = 112) with inflammatory bowel disease, psoriasis/psoriatic arthritis, rheumatoid arthritis, spondylarthritis, and systemic lupus were recruited from participating Canadian medical centers from 2021 to 2023. We focused on log-transformed neutralization (lentivirus methods) as a continuous outcome, with separate models for wild-type and Omicron strains BA.1 and BA.5.ResultsCompared with 30 to 120 days postvaccination, subsequent periods were associated with greater neutralization in unadjusted models for wild-type, BA.1, and BA.5 strains and against the BA.1 strain in adjusted models. Rituximab was associated with lower neutralization for the BA.1 strain in adjusted models, with a similar trend for BA.5. In methotrexate users, there were trends for less neutralization of BA.1 and BA.5 in all unadjusted models, whereas in adjusted models, there was significantly lower neutralization only for the wild type. Three or more doses and Omicron-specific vaccines were both independently associated with better neutralization ability for all three strains. A COVID-19 infection within six months before sampling was associated with higher neutralization of wild type and BA.1 in adjusted analyses. Anti-tumor necrosis factor agents were associated with lower neutralization ability for BA.5 in adjusted analyses.ConclusionNeutralization responses in immunosuppressed individuals with IMID were durable over time and were augmented by more than three doses and Omicron-specific vaccines. Less neutralization was seen with certain medications. Our work clarifies the joint effects of vaccine history, infection, and medications on COVID-19 immunity.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Understanding COVID-19 Risk in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Analysis of SARS-CoV-2 Testing
    Eder, Lihi
    Croxford, Ruth
    Drucker, Aaron M.
    Mendel, Arielle
    Kuriya, Bindee
    Touma, Zahi
    Johnson, Sindhu R.
    Cook, Richard
    Bernatsky, Sasha
    Haroon, Nigil
    Widdifield, Jessica
    ARTHRITIS CARE & RESEARCH, 2023, 75 (02) : 317 - 325
  • [22] Immune response after SARS-CoV-2 vaccination in patients with inflammatory immune-mediated diseases receiving immunosuppressive treatment
    Chamaida Plasencia-Rodríguez
    Ana Martínez-Feito
    Marta Hernández
    Lucia Del Pino-Molina
    Marta Novella-Navarro
    Yolanda Serrano
    Miguel González-Muñoz
    Diana Peiteado
    Gema Bonilla
    Irene Monjo
    Laura Nuño
    Carolina Tornero
    Eduardo López-Granados
    Alejandro Balsa
    Pilar Nozal
    Allergy, Asthma & Clinical Immunology, 19
  • [23] Immune response after SARS-CoV-2 vaccination in patients with inflammatory immune-mediated diseases receiving immunosuppressive treatment
    Plasencia-Rodriguez, Chamaida
    Martinez-Feito, Ana
    Hernandez, Marta
    Del Pino-Molina, Lucia
    Novella-Navarro, Marta
    Serrano, Yolanda
    Gonzalez-Munoz, Miguel
    Peiteado, Diana
    Bonilla, Gema
    Monjo, Irene
    Nuno, Laura
    Tornero, Carolina
    Lopez-Granados, Eduardo
    Balsa, Alejandro
    Nozal, Pilar
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2023, 19 (01):
  • [24] INFLAMMATORY RHEUMATIC DISEASES (IRD) WITH ONSET AFTER SARS-COV-2 INFECTION OR COVID-19 VACCINATION: A COHORT STUDY FROM THE COVID-19 & ASD COLLABORATIVE STUDY GROUP
    Ursini, F.
    Ruscitti, P.
    Addimanda, O.
    Foti, R.
    Raimondo, V.
    Murdaca, G.
    Caira, V.
    Pigatto, E.
    Cuomo, G.
    Lo Gullo, A.
    Cavazzana, I.
    Campochiaro, C.
    Naclerio, C.
    De Angelis, R.
    Ciaffi, J.
    Mancarella, L.
    Brusi, V.
    Marchetti, E.
    Motta, F.
    Visentini, M.
    Lorusso, S.
    De Santis, M.
    De Luca, G.
    Massaro, L.
    Olivo, D.
    Pellegrini, R.
    Luppino, J. M. E.
    Di Cola, I.
    Foti, R.
    Varcasia, G.
    Caso, F.
    Reta, M.
    Dagna, L.
    Selmi, C.
    Iagnocco, A.
    Giacomelli, R.
    Iannone, F.
    Ferri, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 535 - 535
  • [25] Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study
    Hitchon, Carol A.
    Mesa, Christine
    Bernstein, Charles N.
    Marrie, Ruth Ann
    Card, Catherine
    O'Brien, Sheila F.
    Kim, John
    BMJ OPEN, 2023, 13 (05):
  • [26] IMMUNE RESPONSE AFTER COVID-19 VACCINATION DURING MAINTANACE THERAPY IN IMMUNE-MEDIATED INFLAMMATORY DISEASES: AN OBSERVATIONAL COHORT STUDY
    Dayam, R. M.
    Law, Jaclyn C.
    Goetgebuer, Rogier
    Chao, Gary
    Stempak, Joanne M.
    Pereira, Daniel
    Acheampong, Lily
    Rizwan, Saima
    Milgrom, Raquel
    Rymaszewski, Klaudia
    Ganatra, Darshini
    Finkelstein, Naomi
    Croitoru, David
    Lau, Irene
    Law, Ryan
    Girard, Melanie
    Batista, Nathalia Vieira
    Abe, Kento
    Rathod, Bhavisha
    Kitaygorodski, Julia
    Piguet, Vincent
    Chandran, Vinod
    Silverberg, Mark S.
    Gingras, Anne-Claude
    Watts, Tania
    GASTROENTEROLOGY, 2022, 162 (07) : S1006 - S1006
  • [27] Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination
    Hedges, Jodi F.
    Thompson, Macy A.
    Snyder, Deann T.
    Robison, Amanda
    Taylor, Matthew P.
    Jutila, Mark A.
    VACCINES, 2021, 9 (06)
  • [28] A Prospective Cohort Study of COVID-19 Vaccination, SARS-CoV-2 Infection, and Fertility
    Wesselink, Amelia K.
    Hatch, Elizabeth E.
    Rothman, Kenneth J.
    Wang, Tanran R.
    Willis, Mary D.
    Yland, Jennifer
    Crowe, Holly M.
    Geller, Ruth J.
    Willis, Sydney K.
    Perkins, Rebecca B.
    Regan, Annette K.
    Levinson, Jessica
    Mikkelsen, Ellen M.
    Wise, Lauren A.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2022, 191 (08) : 1383 - 1395
  • [29] Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination
    Yamamoto, Shinya
    Yamayoshi, Seiya
    Ito, Mutsumi
    Sakai-Tagawa, Yuko
    Nakachi, Ichiro
    Baba, Rie
    Kamimoto, Shigenobu
    Ogura, Takayuki
    Hagiwara, Shigehiro
    Kato, Hideaki
    Nakajima, Hideaki
    Uwamino, Yoshifumi
    Yagi, Kazuma
    Sugaya, Norio
    Nagai, Hiroyuki
    Saito, Makoto
    Adachi, Eisuke
    Koga, Michiko
    Tsutsumi, Takeya
    Duong, Calvin
    Okuda, Moe
    Murakami, Jurika
    Furusawa, Yuri
    Ujie, Michiko
    Iwatsuki-Horimoto, Kiyoko
    Yotsuyanagi, Hiroshi
    Kawaoka, Yoshihiro
    ISCIENCE, 2023, 26 (07)
  • [30] SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study - the BELCOMID study
    Geldof, Jeroen
    Truyens, Marie
    Sabino, Joao
    Ferrante, Marc
    Lambert, Jo
    Lapeere, Hilde
    Hillary, Tom
    Van Laethem, An
    de Vlam, Kurt
    Verschueren, Patrick
    Padalko, Elizaveta
    Lobaton, Triana
    Vermeire, Severine
    FRONTIERS IN IMMUNOLOGY, 2023, 14